Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

被引：7

作者：

Yelamos, Jose ^{[1
,2
,3
]}

Galindo, Miguel ^{[1
]}

Navarro, Judith ^{[1
]}

Albanell, Joan ^{[1
,4
]}

Rovira, Ana ^{[1
,4
]}

Rojo, Federico ^{[1
,5
]}

Oliver, Javier ^{[6
]}

机构：

[1] Hosp del Mar, Canc Res Program, Med Res Inst IMIM, Barcelona, Spain

[2] Hosp del Mar, Dept Immunol, Barcelona, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

[4] Hosp del Mar, Dept Oncol, Barcelona, Spain

[5] IIS Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain

[6] Inst Parasitol & Biomed Lopez Neyra, Dept Cell Biol & Immunol, Granada, Spain

来源：

ONCOIMMUNOLOGY | 2016年 / 5卷 / 01期

关键词：

Apo2L/TRAIL; EGFR; HER2; monoclonal anti-body; PARP; VEGF; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; NEGATIVE BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE-1; PHARMACOLOGICAL INHIBITION; HOMOLOGOUS RECOMBINATION; ACQUIRED-RESISTANCE; IN-VIVO; ACTIVATION; REPAIR;

D O I：

10.1080/2162402X.2015.1065370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave beta-NAD(+) and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy.

引用

页数：9

共 50 条

[21] Research progress on improving the tumor-targeting of photosensitizers in photodynamic therapy
Yang Y.
Zhao X.
Fan J.
Peng X.
Huagong Xuebao/CIESC Journal, 2021, 72 (01): : 1 - 13
[22] An esterase-activatable curcumin prodrug for tumor-targeting therapy
Liu, Li
Zhang, Lele
Tao, Menglin
Wang, Minghui
Dong, Ling
Hai, Zijuan
CHEMICAL COMMUNICATIONS, 2022, 58 (96) : 13329 - 13332
[23] Tumor-targeting prodrug-activating bacteria for cancer therapy
C-M Cheng
Y-L Lu
K-H Chuang
W-C Hung
J Shiea
Y-C Su
C-H Kao
B-M Chen
S Roffler
T-L Cheng
Cancer Gene Therapy, 2008, 15 : 393 - 401
[24] Tumor-targeting prodrug-activating bacteria for cancer therapy
Cheng, C-M
Lu, Y-L
Chuang, K-H
Hung, W-C
Shiea, J.
Su, Y-C
Kao, C-H
Chen, B-M
Roffler, S.
Cheng, T-L
CANCER GENE THERAPY, 2008, 15 (06) : 393 - 401
[25] Biocompatible tumor-targeting nanocomposites based on CuS for tumor imaging and photothermal therapy
Liang, Li
Peng, Shuwen
Yuan, Zhenwei
Wei, Chen
He, Yuanyuan
Zheng, Jinrong
Gu, Yueqing
Chen, Haiyan
RSC ADVANCES, 2018, 8 (11): : 6013 - 6026
[26] Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models
Jia, Li-Jun
Wei, Dong-Ping
Sun, Qi-Ming
Huang, Yan
Wu, Qiang
Hua, Zi-Chun
CANCER SCIENCE, 2007, 98 (07) : 1107 - 1112
[27] Targeting monoclonal antibodies to the tumor microenvironment for cancer immunotherapy
Hall, Frederick L.
Chawla, Sant P.
Chawla, Neal S.
Gordon, Erlinda M.
CANCER RESEARCH, 2016, 76
[28] CANCER TREATMENT/PHOTODYNAMIC THERAPY Depth no barrier for tumor-targeting light therapy
不详
LASER FOCUS WORLD, 2015, 51 (05): : 65 - 65
[29] Tumor-Targeting Theranostic Polymers
Wei, Ying
Wang, Mingfeng
LANGMUIR, 2025, 41 (12) : 7928 - 7945
[30] Enhancing sensitivity to PARP inhibitors
Sarah Crunkhorn
Nature Reviews Drug Discovery, 2021, 20 (6) : 426 - 426

← 1 2 3 4 5 →